On September 24, 2026, President Trump's nominee to lead the FDA, Dr. Heidi Overton, faced skepticism from Republican senators during her confirmation hearing, particularly on vaccine policy. She reportedly broke with Trump's positions during questioning.
Heidi Overton, President Trump's nominee to lead the Food and Drug Administration, faced Senate questioning on 25–27 September 2026 about vaccines, birth control, and vaping but declined to state whether she believed Trump could ever be wrong. Her evasiveness raised concerns about regulatory independence.
On 24 September 2026, senators questioned FDA commissioner nominee Heidi Overton, an outspoken abortion critic, during her confirmation hearing. Overton would oversee an ongoing FDA safety review of mifepristone, the nation's leading abortion pill, but indicated that the agency's existing review would determine any regulatory changes.
Dr. Heidi Overton appeared before a Senate committee on September 24 for her confirmation hearing as FDA commissioner. During questioning, Overton affirmed that the MMR vaccine is safe and effective but faced scrutiny over her views on abortion medication mifepristone.
On September 24-25, 2026, Dr. Heidi Overton, President Trump's nominee to lead the Food and Drug Administration, testified before the Senate HELP Committee. The hearing tested Senator Susan Collins, an abortion-rights Republican, as Overton declined to say whether Trump can be wrong and dodged questions on fetal contamination.
Dr. Heidi Overton, nominated for F.D.A. director, faced a Senate confirmation hearing on 2026-09-24 over her positions on abortion medication, vaccine recommendations, and food safety. She has previously characterized mifepristone as dangerous and worked to reduce childhood vaccine recommendations.
Dr. Heidi Overton, Trump's nominee to lead the FDA, appeared before the US Senate on 24 September for confirmation hearings where she largely dodged difficult questions on vaccines and abortion pills. The hearing examined her stance on controversial topics affecting the agency's regulatory role.